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Abstract
Context: The National Institute for Health and Care Excellence (NICE) has an explicit 
mandate to include patient and public involvement in the appraisal of medicines to be 
available for funding on the NHS. NICE involves an appraisal committee who are re-
quired to take on board experiential evidence from patient experts alongside 
population- based evidence on clinical and cost- effectiveness when making a decision 
whether to fund a drug.
Objective: This paper considers how NICE Single Technological Appraisal (STA) com-
mittees attempt to incorporate the views of patients in making decisions about fund-
ing medicines on the NHS.
Methods: A prospective design was employed to follow three pharmaceutical prod-
ucts involving three different appraisal committees. Three data collection methods 
were used: analysis of documentary evidence sent by NICE, non- participant unstruc-
tured observations of the open and closed sessions of meetings and qualitative 
interviews.
";||bm]v-m7r-u|b1br-m|vĹUnstructured non- participant observations were carried out 
at nine STA meetings, and 41 semi- structured interviews were undertaken with com-
mittee members from NICE’s STA committees, patient experts, analysts from NICE’s 
project team and drug manufacturers.
Results: Our analysis showed how the committees displayed a preference for an ideal- 
type of patient representative, disagreement among the committee when weighing- up 
patient statements in the STA process and more pre- preparation support for patient 
involvement.
Conclusions: Although NICE has attempted to adopt an approach flexible to patients 
and carers through formal decision- making arrangements that incorporate patient 
views, nonetheless, the processes of the STAs can in fact undermine the very evidence 
collected from patient representatives.
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The role of the National Institute for Health and Care Excellence 
(NICE) is to improve the quality of health and social care in England, 
including making recommendations about the value- for- money of new 
and existing medicines. The goal behind this latter task is to assure 
the consistency of equitable access of drugs to patients across the 
entire NHS, as well as to ensure the efficient use of public finances by 
regulating NHS consumption of expensive drugs, and evaluate “novel” 
medicines against the criteria of cost- effectiveness.1,2 Through NICE, 
the Department of Health has sought to regulate the introduction of 
new and existing medicines and treatments within the NHS, basing its 
decisions on a review of clinical and economic evidence principally, at 
least for single technological appraisals (STAs), provided by the drug 
manufacturer. The advice provided by NICE is aimed at overcoming 
the previously ad hoc, discretionary decisions in order to standardize 
access to health- care technologies across England based on evidence; 
however, the politicization of these decisions has resulted in NICE fac-
ing much criticism and challenges to its legitimacy.3,4
STAs are one of NICE’s decision- making processes in which evi-
dence about a selected technology (often medicines) is evaluated in 
three distinct phases (scoping, assessment and appraisal). In the last 
phase of this process, an independent appraisal committee evaluates 
evidence in a meeting (or multiple meetings), partly held in public 
but with the latter half taking place in a “closed” session. During the 
meeting(s), the committee considers evidence based on clinical and 
cost- effectiveness, as well as statements expressed by patients, com-
missioning experts and clinical specialists.5 The Institute encourages 
patient experts attending the meeting to provide both written and oral 
commentary about their personal view in the current management of 
the condition and the expected role and use of the technology—in par-
ticular how it might provide benefit to patients.
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Patient and public involvement (PPI) within the planning and develop-
ment of health services is by no means a new concept in the domain 
of user involvement;6 in particular, PPI has in recent years in the UK 
become a growing feature in the organization and delivery of health 
care.7-10 Since the mid- 1990s there have been moves towards an, 
“open, accountable and patient- centred service and an attempt to es-
tablish the involvement of service users in health- care services,” and 
within the UK NHS, there have been a number of initiatives giving in-
dividuals and groups a stronger voice within the health service in ac-
tivities such as planning and development, extensive lobbying within 
hospital Trusts11 and involving the public in commissioning decisions 
and strategies.12 Although PPI has become increasingly prevalent, rela-
tively little is known about which approaches work best, when or why, 
or under what circumstances better outcomes can be achieved mak-
ing it difficult to draw conclusions about the effectiveness of different 
involvement approaches.13 One of the key aspects underpinning such 
uncertainty is how PPI contributes to decision making in the review and 
appraisal of new drug therapies. Researchers have questioned whether 
the arrangements for engaging and involving users in the decision- 
making process are effectively addressed through formal structures 
set up by organizations such as NICE in their appraisals processes.14 
This paper considers the contribution patient experts make in NICE’s 
STA committee meetings, identifies what level of participation patient 
experts currently have, and what types of health- care decision- making 
contexts or domains the current model of involvement reflects.
The difficulties in incorporating patient perspectives when ap-
praising new drugs are noted by Milewa. He explains how in one 
respect NICE is charged, “with the production of evidence- based deci-
sions…But in a second regard NICE is politicized in that it has to afford 
interested parties access to the decision- making process, demonstrate 
cognisance of these myriad voices and reflect transparency in atten-
dant rationales for its rulings.”15 Thus, NICE is required to demonstrate 
that it has consulted with various active specialists—not only typical 
experts including clinicians, health economists, NHS managers, phar-
macists and researchers from health technology manufacturers, but 
patient groups who provide detailed witness statements. Milewa ar-
gues that inclusion of various active patient participants, “appears to 
constitute a more inclusive, deliberative, approach to decision making.” 
In pragmatic terms however, Milewa describes the difficulty in imple-
menting these two positions, as NICE attempts to balance these two 
decision- making logics—reasoning according to explicit criteria (clin-
ical and cost- effectiveness) and upholding an equality of status with 
all participants in the appraisal process. In his 2005 qualitative study, 
Milewa found that clinical and professional actors (as noted above) 
appeared to play a major role in debarring, reshaping or admitting the 
more subjective accounts or experientially based forms of evidence 
submitted by patients and carers.16
In the last 5 years, policy reforms in the NHS and in social care 
organizations denote a far greater expectation that patients, service 
users, carers and the public will be involved in decisions regarding the 
delivery of health- care services, as reflected in four key policies: the 
Health and Social Care Act (2012), the NHS Constitution (2012), “Putting 
people at the heart of care (2009) and “Essential Standards of Quality 
and Safety (2010). In line with these wider tendencies in English health 
policy,17 NICE has outlined its own key principles to promoting PPI:
 That lay people, and organizations representing their interests, have 
opportunities to contribute to developing NICE guidance, advice 
and quality standards, and support their implementation, and
 That, because of this contribution, our guidance and other products 
have greater focus and relevance for the people most directly af-
fected by our recommendations.18
Through its 2013 policy paper on Patient and Public Involvement 
Policy, NICE’s commitment to involving patients, service users, carers and 
the public appears integral across its range of guidance, products and 
quality standards documentation. In relation to STAs, NICE’s continued 
commitment to ensuring this level of PPI appears evident. For every STA, 
NICE invites submissions from all patient and carer groups with interests 
relevant to the appraisal, and their written and oral statements must be 
taken on board by the committee involved in the decision making.
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In the context of technological appraisals the main pur-
pose of qualitative research is to explore areas such as pa-
tients experiences of having a disease or condition, their 
experience of having treatment and their views on the ac-
ceptability of different kinds of treatments5
NICE specifically outlines the areas where patient and carer perspec-
tives would provide the most benefit to the appraisal committee; this 
includes consideration of both “majority views and views held by only 
a few patients even if they contradict the majority”; therefore, NICE ap-
pears to invite a spectrum of patient views to be taken into account, even 
in contexts where views may differ. In addition, NICE states that the ap-
praisal committees are keen to incorporate patient perspectives in areas 
where there are gaps in published research that do not adequately cap-
ture outcomes that are important to patients, and help gauge valid clini-
cal outcomes and standardized generic instruments in measuring quality 
of life to the disease or condition.5 Therefore, NICE and its committees 
might find themselves in a potentially incongruous position: how to take 
on board the experiential evidence from individual experts alongside ev-
idence on clinical and cost- effectiveness when reaching a decision about 
whether or not to recommend a drug as cost- effective for NHS use.
Committee members involved in the appraisal process are se-
lected on merit following an open and fair recruitment process where 
posts are publically advertised. The STA selection panel assesses can-
didates’ CVs and supporting letters who best meet the criteria for the 
role, and are then invited to interview. At interview the panel enquires 
about applicants’ skills and experience asking specific questions to 
assess if they meet the person specification. Prospective committee 
members are expected to have experience in health or social care as 
a practising health and social care professionals, or working in asso-
ciation with the wider aspects of health and social care. Members of 
the appraisal committee are selected from a spectrum of backgrounds 
including medical (GPs, consultants, clinicians) and non- medical 
health- care professionals (nurses and other allied health profession-
als), NHS managers, pharmacists, academics (epidemiologists, health 
economists, statisticians and public health practitioners), as well as 
lay experts. NICE therefore seeks to appoint members of the com-
mittees based upon their relevant experience or their specific tech-
nical skills.19 In terms of the patient experts asked to provide witness 
statements to the STA committee meetings, the Public Involvement 
Programme (PIP) manager contacts them in advance to explain what 
their role is, to complete their personal statement and prepare them 
for the meeting.20
While there is a growing emphasis on patient involvement in NICE 
technological appraisal meetings, nonetheless prospects for greater 
participation remain somewhat unclear, and therefore, the expectation 
and assumption of what patient experts may bring to the decision- 
making process varies considerably. Charles and DeMaio present a 
conceptual framework based on three elements of a decision- making 
domain (treatment, service delivery and broad macro- or system level 
decision- making contexts), which incorporates different role per-
spectives (a user of health services, and a public policy perspective), 
taking into account a range of levels of participation (consultation, 
partnership and lay control), thus providing a step towards under-
standing the contribution lay participation may make in health- care 
decision making. This framework helps to delineate the types and 
levels of lay involvement that take place at STA meetings (discussed 
further below), and the implications of this involvement for decision 
making at the meetings.6
In other aspects of its work, NICE appears to have a broader com-
mitment to involving patient experts (such as expert eyewitnesses 
from the voluntary or community sector) through its PIP offering prac-
tical and detailed advice on how individuals can be involved in NICE’s 
individual programmes in public health, health technologies, clinical 
practice or guidance products.21 While NICE’s express commitment 
to incorporating PPI is evident, there have been notable barriers to 
patient experts’ participation in NICE technology appraisal meetings. 
In a survey published by NICE in 2012 of patient experts, respondents 
reported that the level of patient expert participation varied across 
different STA committees, and that their contribution to the appraisal 
meetings was largely dependent upon the committee Chair.20 Gibson 
and colleagues argue that in order for lay engagement to gain full rec-
ognition to complement the analytic and reductionist approaches of 
scientific reason, professionals, including the committee Chair, must 
engage in deliberations outside their traditional professional terrains. 
Thus, the value provided by lay experts is dependent upon the com-
mittee Chair to provide “knowledge spaces” to help establish a new 
terrain where experiential evidence, interpretations and opinions, 
and on the other hand, rigorous evaluations and scientific rationality, 
come together to build “creative dialogues to inform health- care policy 
decisions.”22
Patient experts also reported that the meetings were “very large, 
formal and with a lot of technical language, and that the emphasis on 
clinical and cost- effectiveness overshadowed patient issues.”20 They 
described not feeling able to contribute to issues of paramount im-
portance, and they did not feel sufficiently sure or confident of their 
role in the meetings. Worryingly, some patient experts felt intimidated 
at meetings and, less surprisingly had difficulty following the presen-
tations. The barriers to lay persons’ participation are noted by Gibson 
and colleagues in their examination of the concept of PPI. They ob-
served how difficult, if not impossible it was for lay persons to achieve 
participatory parity in the presence of professionals. They argued 
that current PPI statutes may instil a semblance of equality in par-
ticipation, nonetheless in specific meeting settings, “the abstract and 
technical forms of knowledge that professionals tend to have acquired 
through formal education are highly valued than the practical, experi-
ential knowledge that patients or members of the public may possess.” 
Unfortunately when lay persons sit on prestigious medical committees 
their contribution may be unconsciously undermined, because “they 
do not have access to dominant forms of capital that professionals 
have access to.”22 The patient experts felt that their presence at meet-
ings was largely “tokenistic” and that the patient experience had little 
to do with the committee’s overall decision.20 The literature has em-
phasized such tokenism as one key reason why PPI has thus far had 
limited influence on the organization, planning and delivery of health- 
care services, despite its emphasis in recent policy. Yet, in exploring 
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the role of patients in NICE appraisal decision making, it is important 
to go beyond this narrative to consider the possibility of greater influ-
ence as well as to nuance analyses of the process of marginalization 
where this takes place.
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The study used a prospective design to follow three pharmaceutical 
products through the STA process, which were chosen for variation 
in the socio- cultural resonance of the illness they were designed to 
treat. The final selection included: a drug treating a less “prominent” 
but prevalent chronic illness (Case Study X); a drug treating a high 
profile condition (Case Study Y); and lastly, a drug which treated a rare 
but life- threatening condition (Case Study Z).23,24
The study used an ethnographic research approach using three 
distinct methods of data collection: first, an analysis of documents 
released by NICE on each drug/therapy made available to the pub-
lic online, documents submitted by the pharmaceutical company 
and review documents prepared by independent academic advisors. 
Documentary analysis was undertaken to identify points of conten-
tion, areas of uncertainty in the data, as well as providing the research-
ers contextual information about the drug under assessment.
Second, for each drug appraisal, semi- structured interviews were 
conducted with a purposive cross- sectional sample of the key infor-
mants (see Table 1). Forty- one interviews, both face- to- face (15) and 
telephone (26) (three with NICE staff plus 14 in case study X, 12 in 
case study Y and 12 in case study Z), were carried out. Each interview 
lasted between 45 and 90 minutes, was voice- recorded and was then 
transcribed. The semi- structured interview guide covered topics which 
probed around their experiences of the meeting, how informants dealt 
with issues of uncertainty, whether they felt there were influences in 
the wider social- cultural environment that influenced decision making, 
other external influences in the appraisal process on decision making, 
and how they found working with NICE as an organization.
Lastly, nine non- participant unstructured observations of open 
and closed sessions of the committee meetings were carried out 
across the three case studies. Observational data were collected by 
two researchers who attended each meeting; one researcher recorded 
detailed discussions from the meeting verbatim, while the second re-
searcher collected observational data on key discussions and debates, 
including any major points of uncertainty. It was not possible to utilize 
a structured observational schedule due to the technical nature of 
discussions. The field work was carried out between 2012 and 2014.
Three researchers were involved in the data collection activities 
for the documentary analysis, interviews and non- participant obser-
vations. All three members of the research team brought with them a 
range of meaningful perspectives, experiences and standpoints which 
influenced the research process in terms of data collection and analy-
sis (see Analysis section below).25
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The original study was funded by the Economic and Social Research 
Council (ESRC) on a project entitled “Managing uncertainty within 
NICE technological appraisals: the nature and impact of the ‘social 
features’ of decision- making.” While the proposal originally set out 
to study difficulties in reaching decisions due to multiple logics and 
inputs, the specific issue of patient involvement was a theme that 
emerged from the data in the subsequent analysis phase. Thus, fur-
ther data on how much experience the participants had of PPI in re-
search and in the overall STA process were not covered in the study’s 
objectives.
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Ethical approval for the study was provided by the Ethics Committee 
for Research Council Grants—Social Science and Humanities, ap-
proved by the ESRC subcommittee from the University of Kent 
(25842). In addition, we registered the project under the University’s 
Research Governance Framework (RGF) as the study fell under the 
Department of Health’s RGF.
The main ethical issues encountered concerned potential identifi-
cation of participants, in particular as membership of each of the com-
mittees is published on NICE’s website. It was ensured that reference 
to the drug under appraisal, the corresponding committee and any 
information relating to the participants (including age, gender, years 
working on STAs) was removed to ensure anonymity.
ƑĺƒՊ|Պ11;vv-m7u;1ub|l;m|
The participating departments of NICE gave their approval for the re-
search to be carried out. The initial approach was then made to the 
committee Chairs who provided an agreement by which we gained 
$ ƐՊParticipant type and number of interviews





Case study X 1 1 8 2 2 14
Case study Y 1 1 9 1 0 12
Case study Z 1 1 6 2 2 12
NICE overview 
interviews
– – – – – 3
Total 41
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permission to undertake the non- participatory observations; in addi-
tion, individual consent was obtained from the committee members 
for the closed part of the meetings.
The first contact to recruit interviewees was made face- to- face 
by the researchers who approached all potential participants includ-
ing NICE committee members, as well as external contributors such 
as patient experts, clinical experts, members of specialist assessment 
groups and representatives from the pharmaceutical industry (see 
Table 1). Consent was taken from each of the informants.
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In the analysis presented below, it was considered how the commit-
tee incorporated data primarily from trials about clinical and cost- 
effectiveness with experiential accounts from patients, exploring how 
they synthesized each type of data to reach a decision during a STA 
meeting on whether or not to recommend a drug for availability on the 
NHS. The data from the non- participant observational field notes and 
transcribed informant interviews were first categorized into themes 
and subthemes1 and were then coded using NVIVO by two members of 
the team. Samples of the data were then double- coded and discussed 
between the research team to advance reliability and construct valid-
ity. These critical discussions around the data and its interpretation also 
enabled a more reflexive approach where initial assumptions, or indi-
vidual insights emerging from having conducted particular interviews, 
for example, were able to be challenged and reflected upon. Because 
patient involvement was not one of our initial themes, our analyses 
of this process were arguably less confined by clear expectations but 
more implicit assumptions (based on our reading around NICE) that 
shaped our analytical standpoints and it was important that existing 
arguments (for example regarding tokenism) were not simplistically 
reproduced. Reflexivity was further stimulated by triangulation of our 
data sources (documentary analysis, interviews and non- participant 
observations) within the analysis, which rendered neat conclusions 
about one STA “reality” impossible and forced an acknowledgement of 
the multiple “realities” of decision making for different participants at 
different moments.26 Triangulating the official narratives of written re-
ports with the messiness of decision making as indicated through inter-
views and observations illuminated processes of power while tensions 
between observations (what people did) and interviews (what people 
said they did) also helped us explore the social structures of decision 
making, not least the taken- for- granted aspects.23,27
The analysis undertaken focused upon manifest themes, which 
were themes drawn directly from the interviews and observable con-
tent within the data set, rather than latent themes, which are tacit 
deductions, where participants refer to social distances from certain 
groups.28 Daly et al.29 describe thematic analysis as an emergence of 
themes which suitably describe the subject under investigation, and 
such themes can be manifest or latent, and thus, our analysis of the 
data is a well- recognized approach. The data extracts available from 
the observations were limited, not least because the patient expert 
testimonies came at the latter stages of the open part of the meet-
ing, and thus made up a relatively small part of the interactions at the 
meeting. The patient’s input was discussed later by the committee in 
the closed meetings to different extents across the three cases.
ƒՊ |Պ!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benefits of the drug
The relevance and importance of patients’ perspectives were recog-
nized by the committee members, who generally expressed that these 
views were central to enable a complete appraisal of the drug technol-
ogy under assessment:
 its so amazingly helpful to have people with all different 
perspectives because everybody will have their own, not 
just perspective but their own strengths in interpreting the 
evidence and some people will come from, for example lay 
people, with a sort of common sense lay perspective
(Committee Member)1
The committee member above noted the importance of having a 
pluralistic representation of views at the appraisal meetings as well as 
having a “common sense” perspective. In other respects, members of the 
committee thought the patient accounts helped understand the disease 
or condition better:
But its really useful to have the context of the condition 
put in front of you I think thats the bit where I find the 
patients really help withAnd know, you know, what it is 
like day- to- day living with this condition
(Committee Member)
The Chair then probes the patient experts on the signif-
icance of weight lossA second patient expert said that 
a big problem is weight gain which leads to negative ste-
reotypes and nonadherence so a drug that leads to weight 
loss is attractive
(Observation notes Case Study X)
One committee member spoke about how well a patient presented 
herself with a specific condition, which demonstrated how the drug had 
improved her quality of life:
She said, This is my quality of life so and she seemed 
quite energetic and so NICE [the STA committee] were kind 
of quite quite quite Yeah, they were quite taken by 
how she presented herself etc. because, you know, she was 
a patient
(Committee Member)
1We have withheld reference to each specific case study for the interviews with informants 
in order to preserve anonymity.
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Alongside the usefulness of these insights, however, committee mem-
bers reported that patient accounts were also an area of disagreement 
between members of the committee:
Because, you know, theyre the people who are actually 
suffering and theyre telling you what a huge difference it 
can make to their lives or the the length of time they have 
left so thats sometimes quite a struggleSo its hard its 
hard to keep to stay neutral, I think, at times
(Committee Member)
The informant above acknowledged that even though her role at 
the appraisal meeting was to provide an objective viewpoint into evalu-
ating the evidence alongside the patient perspective; nonetheless, she 
admitted it was hard for her to remain neutral. She empathized with 
the patients and admitted that she found it hard to put personal senti-
ments aside. A recognition of the potential power of the patients’ nar-
ratives was also attached to a wariness among a number of committee 
members.
In one case study, some committee members were critical of pa-
tient experts’ contributions to the appraisal process and questioned 
the merits of their inclusion in meetings. One committee member 
spoke about the validity of including patient experts who had very lit-
tle or no experience of being prescribed the medication under review:
Ive seen impassioned pleas for drugs that are completely 
ludicrous because the person didnt have the drug that 
anyway the combination has been discussed, secondly 
theyve got a particularly difficult case and theyve been 
selected for that reason so I dont think that the patient 
representative is necessarily ever very illuminating
(Committee Member)
The comment above suggests that when patient experts were 
brought in to discuss the nature of the disease, rather than whether the 
drug had an effect, this was less than helpful and raised doubt about the 
credibility of the patient expert instead.
As noted above, the power and credibility of patients’ testimo-
nies led to some misgivings about their influence.30 A further concern 
noted by several committee members was that they felt mistrustful of 
the patient experts due to how they were selected. Several accounts 
suggested that the patients were often selected via patient groups, 
who in turn were seen as having close links with manufacturers due to 
their connection with the manufacturer for example through receipt of 
funds from the pharmaceutical industry:
Ive certainly been aware of it once where it was quite clear 
that a company was heavily supportive of the particular 
sort of patient support group and I found that quite diffi-
cult to be completely objective about
(Committee Member)
More often than not, committee members were suspicious and dis-
approving of patient experts and patient representative organizations 
who were seen to have a close association with the drug manufacturers. 
Committee members also seemed to feel that patient experts’ views were 
too narrowly concerned with having the drug available, rather than seeing 
the bigger picture of rationing and the broader consequences for the NHS.
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The patient experts themselves were mindful of their inclusion at 
the appraisal meetings and acknowledged that they were in many re-
spects, merely representatives without a dominant presence or with 
any significant degree of persuasion in the final decision:
No. I I really felt that second time I interrupted about 
the [name of] surgery, the patient experts really you could 
have almost said we we werent needed there
(Patient Expert)
The second meeting INo, I didnt feel thatI didntI 
think it was slightly unusual circumstances that I was in-
vited back to the second meeting because you wouldnt 
normally be invited backAnd I felt that I wasnt asked 
many questions, which was fine but I didnt really feel I 
needed to be thereI dont think I really me being there 
really added anything to proceedings
(Patient Expert)
The two patient experts quoted above were commenting on two 
separate STA appraisals, yet, both referred to feeling marginalized and 
surmised that their viewpoints were not being taken into account. They 
both questioned why they were invited to attend when they felt they 
“weren’t needed to be there.” The first participant described feeling quite 
aggrieved by the way she was interrupted when asked to comment.
In contrast, another patient expert’s contribution at the meeting 
was commended as particularly compelling as she was able to ar-
ticulate in the language appropriate to the committee the problems 
with the disease as well as her recovery after taking the medicine 
(Observation notes). In an interview with this patient expert, she re-
flected positively about her experience and felt the committee were 
receptive to her account. She was also conscious that she was not a 
typical patient and presented herself well:
I think they listened to what I said. I think maybe in hind-
sight they might not have thought of me as a typical pa-
tient because I was young so that may be in hindsight 
maybe we should have put forward an older person but 
I think, you know, the fact that Ive, you know, Im quite 
confident to talk to people and I know quite a lot about 
the condition myself anyway whereas perhaps an older 
patient might not always.
(Patient Expert)
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In this sense, the individual characteristics and capital of the patient 
expert were influential, while the role of the Chair was also influential. 
Within our observations, the Chairs appeared conscious of the need to 
demonstrate publically that they welcomed the views of patient experts:
the Chair reasserts that the committee particularly 
values the contribution from the lay experts as the char-
ity suggested that if cost effectiveness is the only mea-
sure taken seriously by NICE it casts doubt on patient 
involvement
(Observation notes Case Study Y)
Yet, in the closed sessions disclosed exactly what they thought of 
the drug:
Also the Chair felt it [the medicine] was not innovative al-
though felt the need to mention that one of the charities 
saw it as ground breaking as the committee did not want 
to be accused of not taking the patient experts seriously
(Observation notes Case Study Y)
The actions of the Chair reflect how it was necessary to acknowledge 
the contribution of the patient experts of how they viewed the drug, in 
this case, as innovative. In another case, the Chair drove a discussion 
regarding the plausibility of the quality of life model (which initially was 
questioned) by advocating that the committee would be more flexible in 
accepting this model (even though the case was not entirely clear) as a 




We have already noted that the characteristics and conduct of in-
dividuals (patients or Chairs) could shape the relative influence and 
input of patients:
but if anything I feel the patients are not represented as 
strongly.for them on their behalf and often they come 
in dribs and drabs and sometimes if theyre not assertive 
enough they may not even get to say anything
(Committee Member)
Moreover, evidence from interviews pointed towards deeper struc-
tural issues. This same committee member noted a lack of preparation 
was evident among the patient experts attending, with this leading to 
rather poor contributions and suggested that NICE should support and 
prepare the patient experts through the appraisal meetings:
And not to worry if theyre sitting in the meeting and not 
understanding whats going on because there are bits that 
you wont understand and that type of thing. I think if they 
just had a patient just off the street  Im not sure how 
theyd recruit one  Id hope that they would help a little 
bit more.
(Patient Expert)
So while recruiting “patients off the street” would help overcome the 
issues of trust (and involvement with patient groups) noted earlier, our 
interview and observation data points to concerns about level of prepa-
ration (above) and expertise. At some moments, patient experts were 
asked to comment upon technical data by the committee even though 
their role was not to make an assessment about the drug under appraisal:
[Committee member] asks the patient expert how does a 
patient progress; is this a reasonable characterisation? 
he asks. [Patient expert] says that she cant comment. She 
states that regarding whether patients have reasonable 
quality of life, it depends on different patients. Patients 
are made aware so that they can make the decision for 
themselves
(Observation notes Case Study Y)
The question posed by the committee member about patient prog-
ress was quite unexpected and the patient expert felt compelled to re-
mind the committee that she did not have the expertise to comment, 
which in turn could be seen as publically devaluing her presence at the 
meeting.
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In the analysis presented above, the aim was to consider how NICE 
incorporates patient perspectives within the framework of the STAs 
process. Although NICE provides the formal structures and processes 
in its appraisals for involving and engaging patient groups, the role 
of such groups is confined to the realm of “representation” rather 
than that of a key stakeholder in decision making.14 Of the committee 
members and NICE staff which were interviewed (26) across the three 
STA meetings, the majority recognized the contribution of patient in-
volvement in helping to understand the condition, as well as provid-
ing a representational function for each patient group at a meeting. 
Although the Chair was important in acknowledging the contribution 
of patient views in the appraisals process, their lack of first- hand ex-
perience of PPI diminished the importance of including witness state-
ments in the STA decision- making process. As commissioned by the 
Breaking Boundaries Strategic Review of Public Involvement and recom-
mended in the final report, Going the Extra Mile that “a supportive, 
competent and influential leader [is]…critical to the successful deliv-
ery of involvement.”31 In particular a Chair with previous experiential 
knowledge of public involvement would be well positioned to cham-
pion involvement to promote changes in the institutional and organi-
zational culture of the appraisal meetings.
Barnes et al. argue that as patient experts have been delegated 
a role to that solely of representation, it has caused much confusion 
and vagueness in terms of patient involvement. In pragmatic terms, 
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officials have certain expectations of how patient stories should be 
included in the formal bureaucratic decision- making process, and ex-
actly what they expect patient experts to contribute to. In the case of 
patient involvement in the appraisals process, the model of involve-
ment concurs with what Barnes describes as involvement on the 
periphery in the politics of presence, rather than a politics of patient 
advocacy.32 According to Charles and DeMaio’s6 conceptual frame-
work of lay participation in health- care decision making, the patient 
experts’ presence was primarily consultative representing the lowest 
rung of lay participation providing, “an opportunity for individuals to 
express their views, but offers no guarantee that individual views will 
be taken into account.”
Evidence from this study suggested that involving patients in the 
STA process expanded the level of complexity the committees faced 
as it had increased a sense of tension or conflict between committee 
members. The tensions between committee members were created 
by some having a preference for one type of evidence over another, as 
well as doubt and suspicion towards the patient group, who were re-
garded as colluding with the drug manufacturing industry. In Milewa’s15 
examination of health technology adoption by NICE, he noted a similar 
theme of how in the deliberative process for drug appraisals, patients 
and carers were viewed as, “rarely objective with regard to the value 
of health technologies and some variation in opportunities given to 
different actors to voice their opinions in a supposedly neutral delib-
erative arena.” The expectation that patients should provide evidence 
to aid decision making in a neutral arena appeared to set the patient 
experts up against the committee, as patient statements were not pre-
sented in official spaces of knowledge production to be taken as robust 
evidence alone.22 Moreira33 argues that rationing decisions need to be 
more transparent, accountable and democratic, only then can uncer-
tainties be accepted when fully explored in a process of co- production. 
Organizations such as the National Institute for Health Research’s 
INVOLVE advocate greater patient involvement in research, and as 
shown in Going the Extra Mile the salience of co- production enables 
the public, researchers and health- care professionals to work together 
to encourage collaboration and underline the value of people’s exper-
tise through experience in the design and delivery of research.31
In his examination of the role of patient organizations in health 
technology assessment (HTA), Moreira stipulates how there is uncer-
tainly and a lack of theoretical understanding regarding the knowledge 
and expertise brought by patient representatives and organizations to 
HTA processes. He puts forward a model or typology of patient organi-
zations to understand how their epistemic identities are a function of a 
relationship between knowledge activities and network organizations. 
These types of organizations are (A) robust hybrid, (B) weak hybrid, 
(C) weak focused or (D) robust focused. According to Moreira,34 using 
this model to underpin PPI in HTA provides a sound theoretical basis 
that acknowledges how different forms of engagement contribute to 
wider knowledge- making; in addition, it would mean relying less on 
the expert- lay boundary and opening up membership to hybrid com-
mittees where experts, practitioners and patients articulate the rela-
tionship between the evidence base and circumstances under which 
the technology is used.
In many respects, patient experts are tasked with performing a 
conflicting role where they are expected to present themselves as a 
credible patient while at the same time performing the role of a char-
ismatic patient representative. In this study, it was found that patient 
experts who appeared at committee meetings were atypical, as they 
had been able to contribute to formal meeting settings, and, those 
invited did not reflect the archetypal patient. Patient experts who 
attended the meetings had two main reasons for their participation, 
the first as a patient sufferer with the condition or disease, then as 
the enigmatic storyteller or marketer advocating the patient group. In 
these circumstances, the committee placed the patient experts in a 
position where they foresaw their contribution as an aid to reaching a 
decision in a neutral public forum, but when presented with a patient 
statement, they found their impassioned accounts too emotional or 
hard to handle.35
Evidence from this study did show that the overriding priority 
of the committee was to appraise the technology in terms of cost- 
effectiveness and the extent to which it fell in or outside the threshold 
set by NICE.24 In one of our cases, the technology was far too expen-
sive and a decision not to recommend was made after two meetings 
which may explain why there was limited patient expert involvement. 
However, in the other two cases, there was considerable more un-
certainty about the incremental cost- effectiveness ratio and possibly 
therefore more space for patient expert influence.
Notwithstanding the study showed that throughout the process 
for all three cases, social influences on decision making were both ex-
plicit and implicit, suggesting that the discourse on cost- effectiveness 
was overriding and apparent in formally documented meetings, but 
contributions from patient experts also had a tacit impact on the ap-
praisal throwing open debate between committee members around 
rigorous evidence vs patient witness statements. This study also only 
focused on three of the four appraisal committees, although there is 
no reason why the one not included should adopt a different approach 
to the importance of incorporating patient expert perspectives.
Although NICE has implemented some pioneering initiatives to in-
corporate patient perspectives, these initiatives have left some patient 
groups feeling that their role at the STAs has been largely peripheral 
and perhaps even tokenistic. Some patient representatives questioned 
whether they would accept an invitation to attend another meeting 
in the future. Patient experts described feeling unsupported in their 
attendance at meetings and were in some instances dismayed that 
other lay experts would not be able to contribute to meetings given 
the technical nature of discussions.20 NICE’s attempts to engage with 
patients experts in STAs have helped to exclude the very groups the 
appraisal system has intended to involve. While NICE declares values 
and aspirations appearing to be open, transparent, participatory and 
pluralist in its involvement structure, yet in practice, the process is a 
closely managed, unitary system and a top- down model, where sala-
ried professionals run a highly regulated public participation process. 
Their approach to public involvement has been predominantly tech-
nicist or an instrumental approach, without any overriding concern 
for a pluralist involvement structure where a diversity of views can be 
publically articulated.22
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It has been shown that the role of patient representatives at ap-
praisal meetings differed considerably—while some patient experts 
were described as helping the committee understand the disease/
condition, in other respects they were also seen as advocates of the 
new drug therapy. It would appear that NICE needs to provide much 
greater guidance and clarity over the roles and contributions it expects 
patients to make and how their statements and submissions might fit 
into the decision- making framework.6 The blueprint for positive out-
comes and greater impact for PPI is recommended in the RAPPORT 
study by Wilson et al. who put forward six salient actions for effective 
PPI, the first of which is aimed at defining the purpose, role and struc-
ture of PPI. Having a clearly defined role is paramount for NICE to be 
able to carve out a bespoke function for patient experts, to under-
stand where in the decision- making framework patient experts reside 
and what purpose their contribution makes at the appraisal meetings 
and within wider STA deliberations.36
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The evidence from this study has shown that patient experts have 
provided a symbolic and representative function at committee 
meetings where the patient voice is relegated to the periphery 
of participation. The formal appraisal processes and structures 
set up by NICE still appear to fall short of creating knowledge 
spaces where committee members weigh up different types of 
evidence both experiential accounts alongside rigorous evidence 
about clinical and cost- effectiveness. The results show that de-
spite laying out an explicit commitment to incorporating patient 
perspectives through its PPI policy, the arrangements for engag-
ing and involving users through its deliberative processes in fact 
marginalize the very groups it has sought inclusion for at STA ap-
praisal meetings.
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